FDA OKs Updated Moderna and Pfizer-BioNTech COVID-19 Vaccines
The FDA has approved and authorized updated Moderna and Pfizer-BioNTech COVID-19 vaccines for the 2024-2025 season, designed to target current variants.
The FDA has approved and authorized updated Moderna and Pfizer-BioNTech COVID-19 vaccines for the 2024-2025 season, designed to target current variants.
The FDA has approved and authorized updated Moderna and Pfizer-BioNTech COVID-19 vaccines for the 2024-2025 season, designed to target current variants.
Read MoreA 50 µg dose of Moderna’s bivalent booster candidate, mRNA-1273.214, demonstrated superior neutralizing antibody response against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine.
Read MoreThe US FDA has approved the Moderna COVID-19 Vaccine (marketed as “Spikevax”) for the prevention of COVID-19 in individuals 18 years of age and older.Â
Read MoreThe FDA has reported increased risks of myocarditis and pericarditis following vaccination with the Moderna and Pfizer-BioNTech COVID-19 vaccine.
Read More